Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Department of Health Sciences, University of York, York, UK.
J Clin Epidemiol. 2023 Jun;158:149-165. doi: 10.1016/j.jclinepi.2023.04.005. Epub 2023 Apr 24.
Randomized controlled trials remain the reference standard for healthcare research on effects of interventions, and the need to report both benefits and harms is essential. The Consolidated Standards of Reporting Trials (the main CONSORT) statement includes one item on reporting harms (i.e., all important harms or unintended effects in each group). In 2004, the CONSORT group developed the CONSORT Harms extension; however, it has not been consistently applied and needs to be updated. Here, we describe CONSORT Harms 2022, which replaces the CONSORT Harms 2004 checklist, and shows how CONSORT Harms 2022 items could be incorporated into the main CONSORT checklist. Thirteen items from the main CONSORT were modified to improve harms reporting. Three new items were added. In this article, we describe CONSORT Harms 2022 and how it was integrated into the main CONSORT checklist and elaborate on each item relevant to complete reporting of harms in randomized controlled trials. Until future work from the CONSORT group produces an updated checklist, authors, journal reviewers, and editors of randomized controlled trials should use the integrated checklist presented in this paper.
随机对照试验仍然是干预措施效果的医疗保健研究的参考标准,报告益处和危害两者都是至关重要的。《临床试验报告统一标准》(主要的 CONSORT)声明包括一项关于报告危害的条目(即,每组中所有重要的危害或意外影响)。2004 年,CONSORT 小组制定了 CONSORT 危害扩展;然而,它并没有得到一致的应用,需要进行更新。在这里,我们描述了 CONSORT 危害 2022 版,它取代了 CONSORT 危害 2004 清单,并展示了如何将 CONSORT 危害 2022 条目纳入主要 CONSORT 清单。从主要 CONSORT 中修改了 13 个项目以改进危害报告。添加了三个新项目。在本文中,我们描述了 CONSORT 危害 2022 版以及它如何被纳入主要 CONSORT 清单,并详细说明了与随机对照试验中完整报告危害相关的每个项目。在 CONSORT 小组未来的工作产生更新的清单之前,随机对照试验的作者、期刊审稿人和编辑应使用本文中提出的综合清单。